WAVE.
WAVE. WE'RE LIVE IN HARTFORD.
LISSETTE NUNEZ FOX 61 NEWS.
>>
>>
>> ALL
>> ALL RIGHT, LISSETTE, THANK YOU.
NOW THERE ARE A LOT OF NEW
DEVELOPMENTS TO BE ON
THE LOOKOUT FOR OVER THE NEXT
COUPLE OF WEEKS.
>>
>>
>> YES,
>> YES, CERTAINLY LIGHT AT THE END
OF THE TUNNEL.
NOT THERE YET THOUGH, OF
COURSE.
COURSE.
COURSE. CORBETT, 19, STILL SURGING
ACROSS CONNECTICUT AND RIGHT
NOW.
NOW.
NOW. JOINING US TO TALK MORE ABOUT
THAT AND MORE ABOUT THE VACCINE
AND DISTRIBUTION, DR. DAVID
BANNOCK FROM UCONN HEALTH.
GOOD MORNING, DOCTOR.
ARE YOU THERE WITH US?
THERE YOU ARE.
YES.
YES.
YES. YES,
YES. YES, I AM.
THANKS FOR HAVING ME.
YES.
YES.
YES. GLAD
YES. GLAD TO HAVE YOU HERE.
ALL RIGHT.
ALL RIGHT. FIRST QUESTION SOME HEALTH
EXPERTS BELIEVE WE ARE JUST NOW
SEEING THE COVE AT 19 CASES
RELATED TO THE THANKSGIVING
HOLIDAY.
HOLIDAY.
HOLIDAY. WHAT ARE YOU STARTING TO SEE?
DO YOU BELIEVE THAT'S TRUE?
>>
>>
>> SO
>> SO I
>> SO I DO THINK THAT OVER
THE PAST COUPLE OF WEEKS
HOSPITALS THROUGHOUT THE STATE,
THROUGHOUT THE COUNTRY ARE
STARTING TO SEE INCREASING
CASES.
CASES.
CASES. YOU KNOW, I THINK SOME OF THIS
IS CAN BE ATTRIBUTED TO
THE THANKSGIVING HOLIDAY AND
GATHERINGS ASSOCIATED WITH THAT
AS WELL AS TRAVEL.
BUT I THINK THE COLDER WEATHER,
THE CONGREGATING INDOORS, YOU
KNOW, ALL OF IT COMING TOGETHER
TO LEAD TO THE RISE IN CASES.
WE SORT OF ANTICIPATED THIS
MIGHT HAPPEN IN THE WINTER TIME
AND YOU KNOW, IT'S WHAT WE'RE
SEEING RIGHT NOW ON THE GROUND.
WE'RE SEEING A LOT OF PEOPLE
RIDING IN WITH A SIMILAR KIND
OF QUESTION.
OF QUESTION. >>
>>
>> I
>> I HAVE
>> I HAVE ONE IN FRONT.
PAUL BRADLEY FROM BEACON FALLS
WROTE IN TO SAY IF I GET BOTH
THE VACCINE, BOTH SHOTS, WHY
WOULD I NEED TO WEAR A MASK
AFTER THAT AFTER ALL, I MEAN IF
I'M NOT GOING TO GET THE VIRUS
DOESN'T STAND TO FOLLOW THAT I
WOULDN'T BE ABLE TO GIVE IT TO
SOMEBODY ELSE.
SOMEBODY ELSE. >>
>>
>> SO
>> SO I
>> SO I THINK THAT'S A REALLY
IMPORTANT QUESTION.
IMPORTANT QUESTION. YOU KNOW, AS WE KNOW THAT
INDIVIDUALS ARE GOING TO BE
VACCINATED.
VACCINATED. WHAT WE'RE SEEING FROM
THE CLINICAL TRIALS IS THAT
THE VACCINE IS VERY EFFECTIVE
IN PREVENTING DISEASE AND IT'S
EXTREMELY EFFECTIVE IN
PREVENTING SEVERE DISEASE AND
HOSPITALIZATION LEVEL ILLNESS.
SO THEY'RE GETTING VACCINE IS
IMPORTANT ON THE INDIVIDUAL
LEVEL.
LEVEL.
LEVEL. YOU KNOW WHAT WE'RE STILL
WAITING FOR IN TERMS OF DATA IS
HOW MUCH IT PREVENTS SPREADING
THE VIRUS.
THE VIRUS. SO WHETHER INDIVIDUALS WHO ARE
VACCINATED MAY STILL HAVE SORT
OF A VERY MILD AMOUNT OF VIRUS
THAT WOULD SHED THAT WOULDN'T
NECESSARILY CAUSE THEM TO BE
SICK BUT STILL COULD SPREAD TO
OTHERS.
OTHERS.
OTHERS. AND THAT'S THE DATA THAT'S
GOING TO COME FORWARD.
BUT I THINK, YOU KNOW,
THE VACCINE IS STILL GOING TO
BE A CRITICAL ASSET IN OUR
TOOLKIT TO BATTLE OVER 19 AND
EVENTUALLY GET THIS BEHIND US.
>>
>>
>> I
>> I KNOW
>> I KNOW YOU DON'T LIKE TO
SPECULATE DOCTORS GENERALLY AS
A RULE BUT I MEAN IS THERE
REASON TO BE OPTIMISTIC THAT
THIS VACCINE WILL ALSO
DRSTICALLY CUT DOWN ON
PEOPLE'S ABILITY TO TRANSMIT
THE VIRUS AS WELL?
I MEAN IS THAT REASONABLE AT
LEAST HOPED FOR?
>>
>>
>> I
>> I THINK SO.
I THINK YOU KNOW, FROM WHAT
WE'VE SEEN WITH OTHER TYPES OF
VIRUSES AGAINST RESPIRATORY
OTHER TYPES OF VACCINES AGAINST
RESPIRATORY VIRUSES, THERE IS
THAT PROTECTION THAT EVEN IF
ONE DOES ACQUIRE THE VIRUS,
THE AMOUNT THAT'S THERE IS MUCH
LESS.
LESS.
LESS. THEREFORE THERE'S LESS VIRAL
SHEDDING, LESS TRANSMISSION TO
OTHERS.
OTHERS.
OTHERS. THAT'S POTENTIAL TRANSMISSION
TO OTHERS.
TO OTHERS. SO I THINK THAT POTENTIAL IS
THERE AND I THINK WE DO HAVE TO
GET THE DATA ON THAT.
BUT I THINK THERE'S A LOT OF
OPTIMISM BASED ON WHAT WE'VE
SEEN WITH OTHER TYPES OF
VACCINES THAT THAT'LL BE
THE CASE.
THE CASE.
THE CASE. BUT IN THE MEANTIME, YOU KNOW,
WE HAVE TO DOUBLE DOWN ON OUR
VIGILANCE WITH THE MASKING AND
THE OTHER PROTECTIVE MEASURES
THAT ARE IN PLACE.
ANY IDEA WHEN THAT DATA WOULD
COME OUT?
COME OUT?
COME OUT? >>
>>
>> WOULD
>> WOULD THIS BE AFTER
THE VACCINES ARE DISTRIBUTED?
>>
>>
>> SO
>> SO I
>> SO I THINK THE DATA IS GOING TO
CONTINUE TO COME IN THE WEEKS
AND THE MONTHS AHEAD.
>>
>>
>> NO,
>> NO, THE TRIALS THE PHASE 3
CLINICAL TRIALS HAVE BEEN QUITE
LARGE.
LARGE.
LARGE. I
LARGE. I MEAN UPWARDS OF 60000
INDIVIDUALS INCLUDING THESE
TRIALS.
TRIALS.
TRIALS. BUT YOU KNOW, WHEN WE THINK
ABOUT ROLLING OUT THE VACCINE
TO ALL OF OUR HEALTH CARE
WORKERS TO ALL OF OUR LONG TERM
CARE FACILITY PATIENTS, YOU
KNOW, OVER A PERIOD OF WEEKS
WE'RE GOING TO GET MILLIONS OF
DOSES OUT THERE AND THAT DATA
IS GOING TO BE COLLECTED ON AN
ONGOING BASIS.
ONGOING BASIS. SO I THINK, YOU KNOW, THE FDA
IS REALLY ATTENTIVE TO THAT AND
HAS PLENTY OF SYSTEMS IN PLACE
TO COLLECT THAT DATA AND THAT
DATA IS GOING TO BE RELEASED AS
IT COMES IN AND WE'LL LEARN
MORE AND MORE IN THE COMING
WEEKS AND MONTHS.
>>
>>
>> DR.
>> DR. DAVID BANNOCK, YOU HAVE
TAKEN A LOT OF TIME TO GIVE US
YOUR INSIGHTS AND YOU.
THANK YOU FOR DOING IT ONCE
AGAIN.
AGAIN.
AGAIN. I'M SURE WE'LL BE TALKING TO
YOU AGAIN IN THE NEXT COUPLE
DAYS.
DAYS.
DAYS. THANKS FOR HAVING ME.
IT'S GOOD TO HAVE YOU ON.
>>
>>
>> AND
>> AND HE
>> AND HE BRINGS UP A GOOD POINT
EVEN THE FDA IS SAYING A LOT OF
THESE PEOPLE WHO ENROLLED IN
THESE TRIALS, THE TRIALS ARE
STILL GOING ON.
WELL, WE'VE GOTTEN A LOT OF
ANSWERS.
ANSWERS.
ANSWERS. OF COURSE A LOT OF YOU OUT
THERE STILL HAVE CONCERNS ABOUT
LONG TERM EFFECTS AND WHAT WE
JUST WON'T KNOW UNTIL WE GET TO
THE LONG TERM.
BUT AGAIN, IT IS USUALLY
REASONABLE TO ASSUME THAT
THE LONGER WE GO HERE AND WE'VE
GONE FOR A WHILE THE LESS AND
LESS LIKELIHOOD THERE ARE THAT
THERE ARE GOING TO BE A LOT OF
LONG TERM SERIOUS ADVERSE
EFFECTS AND WAIT